Kazia Therapeutics Ltd ADR Cash Flow Conversion Efficiency
Kazia Therapeutics Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Kazia Therapeutics Ltd ADR (KZIA) has a cash flow conversion efficiency ratio of 0.499x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.14 Million) by net assets ($-8.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kazia Therapeutics Ltd ADR (1999–2025)
Cash flow conversion efficiency of Kazia Therapeutics Ltd ADR from 1999 to 2025. This chart illustrates how Kazia Therapeutics Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Kazia Therapeutics Ltd ADR for real-time trading data and today's change.
Kazia Therapeutics Ltd ADR Cash Flow Conversion Ratio Explained
Kazia Therapeutics Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kazia Therapeutics Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kazia Therapeutics Ltd ADR ranked by their cash flow conversion efficiency. Also see market value of Kazia Therapeutics Ltd ADR for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NEW ZEALAND RURAL
F:8UK
|
N/A |
|
GTS Internasional Tbk PT
JK:GTSI
|
0.175x |
|
Fecon Foundation Engineering and Underground Construction JSC
VN:FCN
|
0.096x |
|
Haemato AG
HM:HAEK
|
N/A |
|
Panin Sekuritas Tbk
JK:PANS
|
0.079x |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
0.029x |
|
Aker Technology Co Ltd
TWO:6174
|
-0.004x |
|
Showbox Corp
KQ:086980
|
0.346x |
Annual Cash Flow Conversion Efficiency for Kazia Therapeutics Ltd ADR (1999–2025)
The table below shows the annual cash flow conversion efficiency of Kazia Therapeutics Ltd ADR from 1999 to 2025. Review Kazia Therapeutics Ltd ADR free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-8.30 Million | $-13.28 Million | 1.600x | +67.24% |
| 2024-06-30 | $-10.02 Million | $-9.58 Million | 0.956x | +176.05% |
| 2023-06-30 | $12.05 Million | $-15.16 Million | -1.258x | -0.98% |
| 2022-06-30 | $18.27 Million | $-22.76 Million | -1.246x | -417.44% |
| 2021-06-30 | $37.85 Million | $-9.11 Million | -0.241x | +61.41% |
| 2020-06-30 | $14.12 Million | $-8.81 Million | -0.624x | -31.63% |
| 2019-06-30 | $14.17 Million | $-6.71 Million | -0.474x | -5.27% |
| 2018-06-30 | $19.24 Million | $-8.66 Million | -0.450x | +0.26% |
| 2017-06-30 | $25.34 Million | $-11.43 Million | -0.451x | -27.82% |
| 2016-06-30 | $33.93 Million | $-11.98 Million | -0.353x | -171.96% |
| 2015-06-30 | $44.36 Million | $-5.76 Million | -0.130x | +96.79% |
| 2014-06-30 | $1.41 Million | $-5.71 Million | -4.043x | -135.09% |
| 2013-06-30 | $5.11 Million | $-8.79 Million | -1.720x | -19.66% |
| 2012-06-30 | $5.11 Million | $-7.35 Million | -1.437x | +27.00% |
| 2011-06-30 | $4.42 Million | $-8.70 Million | -1.969x | -56.23% |
| 2010-06-30 | $13.18 Million | $-16.61 Million | -1.260x | -76.02% |
| 2009-06-30 | $28.77 Million | $-20.60 Million | -0.716x | -26.89% |
| 2008-06-30 | $35.62 Million | $-20.10 Million | -0.564x | -72.36% |
| 2007-06-30 | $44.68 Million | $-14.63 Million | -0.327x | -1.07% |
| 2006-06-30 | $44.59 Million | $-14.44 Million | -0.324x | -52.98% |
| 2005-06-30 | $60.25 Million | $-12.76 Million | -0.212x | +3.34% |
| 2004-06-30 | $47.82 Million | $-10.48 Million | -0.219x | -58.72% |
| 2003-06-30 | $42.24 Million | $-5.83 Million | -0.138x | -11.68% |
| 2002-06-30 | $54.07 Million | $-6.68 Million | -0.124x | +63.23% |
| 2001-06-30 | $101.72 Million | $-34.18 Million | -0.336x | +5.51% |
| 2000-06-30 | $52.73 Million | $-18.75 Million | -0.356x | +19.47% |
| 1999-06-30 | $47.49 Million | $-20.97 Million | -0.442x | -- |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more